This study is a prospective randomized trial with 242 IUI cycles. Patients are randomized in two groups including 121 cycles in each group. A total of 255 cycles in 167 patients are finally recruited. In the first group, the patients will be treated with triptorelin (Gonapeptyl®) in their luteal phase. As for the other group, the patients will undergo the luteal phase without any supportive medication. This study is going to clarify the role of the gonadotropin agonist (triptorelin acetate, Gonapeptyl®) as a luteal phase supporter. The benefit of the treatment is measured by the numbers in the live birth and clinical pregnancy rates.

Inclusion Criteria:

• - Patients with ovarian stimulation cycles preparing to insemination
• Patients with medical ovarian stimulation protocols including GnRH agonist, aromatase inhibitors and different combinations of GnRH agonists and aromatase inhibitors are included
• Patient's willingness to participate in the study

Exclusion Criteria:

• - Failure in the ovarian stimulation cycle
• Failures in executing the insemination
• Failures in giving the sperm sample
• Major troubles in sperm parameters leading to an inadequate sample to accomplish intrauterine insemination
• Patients with primarily planned progesterone luteal support